Patients with bullous skin disease in a high‐epidemic COVID‐19 area, Bergamo, Italy

Carugno, Andrea; Sena, Paolo; Raponi, Francesca; Test, Elisa Robustelli; Vezzoli, Pamela

doi:10.1111/bjd.19266

Cited by 14 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only 3 (0.4%) patients demonstrated limited control of their AIBD. 14 , 17 , 57 Results from this preliminary systematic analysis suggest that AIBD patients on immunomodulatory therapies are basically not at an increased risk for severe or fatal COVID-19, as in the general population severe COVID-19 was about 15% and the overall COVID-19 mortality rate was estimated 1.5-3.6%. In conclusion, the pandemic generally does not have a negative effect on have the course of AIBD; therefore, delays or discontinuation of important immunomodulatory treatment should be avoided.…”

Section: General Overview and Expert Recommendations On Treatment Strmentioning

confidence: 89%

See 1 more Smart Citation

Impact of COVID-19 on autoimmune blistering diseases

Drenovska

Tanev²,

Joly

2021

Clinics in Dermatology

View full text Add to dashboard Cite

Since the beginning of the COVID-19 outbreak, attention has gradually moved from the respiratory manifestations of the disease toward its dermatologic aspects. The need for wearing personal protective measures and their cutaneous side effects, detection of related or specific COVID-19 skin eruptions, and the evaluation of certain risk groups of immunosuppressed dermatologic patients have initiated significant discussions about various therapeutic interventions and, in particular, about biologic therapy for psoriasis and for autoinflammatory, orphan, or malignant cutaneous disorders. Autoimmune bullous dermatoses have been of concern due to their chronic course, at times life-threatening prognosis, and the need for prolonged and often aggressive immunomodulatory therapy. We have summarized the current knowledge regarding the impact of COVID-19 infection on autoimmune bullous dermatoses, including recommendations for the main treatment strategies, available patient information, and the registries organized for documentation during the COVID-19 pandemic.

show abstract

Section: General Overview and Expert Recommendations On Treatment Strmentioning

confidence: 89%

“…All patients were in remission and therapeutic regimens were preserved, except for hospitalized cases in which immunosuppressive treatment was discontinued. 17 …”

Section: The Pemphigus Group and Covid-19mentioning

confidence: 99%

Impact of COVID-19 on autoimmune blistering diseases

Drenovska

Tanev²,

Joly

2021

Clinics in Dermatology

View full text Add to dashboard Cite

show abstract

“…There are a limited number of studies investigating the course of pemphigus in patients infected with SARS‐CoV‐2. In an Italy‐based study including 31 patients with pemphigus, 7 patients (1 male, 6 female; mean age: 68.3 ± 9.7) experienced COVID‐19 suspected symptoms 10 . Five patients had comorbidities including hypertension (n = 1), neurologic/psychiatric diseases (n = 2), dyslipidemia (n = 1), and neoplasia (n = 1).…”

Section: Methodsmentioning

confidence: 99%

“…For all patients taking systemic corticosteroid treatment, the current dosage was not deemed immunosuppressive and no patient independently suspended their current treatments. Ongoing corticosteroid or immunosuppressive treatment has only been discontinued for the hospitalized patient 10 . In an Iran‐based study, a total of 45 patients with pemphigus who underwent rituximab therapy between 2014 and 2020 were included.…”

Section: Methodsmentioning

confidence: 99%

Pemphigus and COVID ‐19: Critical overview of management with a focus on treatment choice

Elmas

Demirbaş

Türsen

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

COVID-19 is a serious multisystem disease caused by severe acute respiratory syndrome coronavirus 2. Due to the COVID-19 crisis, that still keeps its impacts worldwide, numerous scheduled medical activities have been postponed and this interruption has a potential to modify the management of many cutaneous conditions including pemphigus. This narrative review aims to discuss the management of pemphigus in the era of COVID-19, considering the necessity to balance suitable pemphigus treatment with minimal risk of COVID-19-related mortality and morbidity. The data on the effect of treatments used for pemphigus on COVID-19 are limited. However, the evidence to manage patients properly is evolving and our knowledge is updated. Current expert recommendations include that patients with pemphigus should be informed clearly to avoid mismanagement and they should be monitored regularly for symptoms of COVID-19. Patients with mild disease can be managed with topical or intralesional corticosteroids, dapsone, or doxycycline. Systemic corticosteroids should be tapered to the lowest effective dose during the pandemic. Prednis(ol)one ≤10 mg/d can be continued in patients with COVID-19 while prednis(ol)one >10 mg/d may be reduced considering the activity of the disease. Conventional immunosuppressive therapies should only be discontinued in confirmed cases of COVID-19. Postponing rituximab treatment should be considered on a case by case basis. Intravenous immunoglobulin is not likely to increase the risk of infection and may be considered a safe option in patients with COVID-19. Given the psychological burden brought by COVID 19, online or face-to-face psychological support programs should be considered.

show abstract

“…The virus is easily spread by speech droplets airborne from symptomatic and asymptomatic carriers ( Stadnytskyi et al, 2020 ). Risk factors to COVID-19 may include household plumbing, large family cluster, overcrowding, male sex, comorbidities like hypertension, bullous pemphigoid and pemphigus vulgaris patients, cancer patients, renal disease, glutathione deficiency, race, and socioeconomic status ( Rodriguez-Lonebear et al, 2020 ; Ikitimur et al, 2020 ; Zemlin and Wiese, 2020 ; Escalera-Antezana et al, 2020 ; Carugno et al, 2020 ; Bhargava et al, 2020 ; Tian et al, 2020 ; Polonikov, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Where are we with understanding of COVID-19?

Akula

McCubrey

2020

Advances in Biological Regulation

View full text Add to dashboard Cite

Coronavirus disease 2019 caused by SARS-CoV-2 originated from China and spread across every corner of the world. The scientific interest on COVID-19 increased after WHO declared it a pandemic in the early February of 2020. In fact, this pandemic has had a worldwide impact on economy, health, and lifestyle like no other in the last 100 years. SARS-CoV-2 belongs to Coronaviridae family and causes the deadliest clinical manifestations when compared to other viruses in the family. COVID-19 is an emerging zoonotic disease that has resulted in over 383,000 deaths around the world. Scientists are scrambling for ideas to develop treatment and prevention strategies to thwart the disease condition. In this review, we have attempted to summarize the latest information on the virus, disease, prevention, and treatment strategies. The future looks promising.

show abstract

Patients with bullous skin disease in a high‐epidemic COVID‐19 area, Bergamo, Italy

Cited by 14 publications

References 6 publications

Impact of COVID-19 on autoimmune blistering diseases

Impact of COVID-19 on autoimmune blistering diseases

Pemphigus and COVID ‐19: Critical overview of management with a focus on treatment choice

Where are we with understanding of COVID-19?

Contact Info

Product

Resources

About